Hyderabad: Bharat Biotech International Limited (BBIL) has reportedly submitted 90 per cent of paperwork to WHO for acquiring emergency use itemizing (EUL) for the Covaxin vaccine.
During a dialogue on acquiring the World Health Organisation’s authorisation for emergency use itemizing for Covaxin, Bharat Biotech Ltd advised the Central authorities that the remaining paperwork are anticipated to be submitted by June.
However, the WHO has stated that “more information” is “required” for emergency use itemizing (EUL) for its Covaxin vaccine for Covid-19.
As reported by information company PTI, the most recent ‘Status of Covid-19 Vaccines within WHO EUL/PQ evaluation process’ steerage doc dated May 18 obtainable on web site of WHO claims that Bharat Biotech submitted EOI (Expression of Interest) on April 19 and that “More information required”. According to the report, a pre-submission assembly is anticipated “to be deliberate May-June 2021″.
Accoding to the health agency, submissions for prequalification or listing under the emergency use procedure are confidential, WHO published the results only after the a product submitted for assessment is found to meet the criteria for listing.
Bharat Biotech is in the final stages of negotiations with the Food and Drug Administration of the US for conducting small-scale phase-III clinical trials of Covaxin in the United States.
Meanwhile, the Union Health Ministry reported that the cumulative number of COVID-19 vaccine doses administered in the country exceeded 19.84 crores (19,84,43,550) as per the 8 pm provisional report on Monday, May 24.
Check out below Health Tools-
Calculate Your Body Mass Index ( BMI )